Latest news with #ZomedicaCorp
Yahoo
21-05-2025
- Business
- Yahoo
Zomedica Launches Enhanced Equine Insulin Assay for the TRUFORMA(R) Diagnostic Platform Featuring an Extended Range and Automatic Sample Dilution
The TRUFORMA Platform now has the widest dynamic range (without manual dilution) available either at the Point of Care or from a Reference Lab ANN ARBOR, MI / / May 21, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced an update to one of their fastest growing assays, insulin for equine plasma. This update increases the test's already industry-leading point of care dynamic range and adds a new function, automatic sample dilution, that allows a veterinarian to measure insulin at the highest levels with no additional steps or increase in time-to-result on the TRUFORMA In-Clinic Biosensor Testing Platform. "When we introduced our equine insulin assay in October of 2024, one of the most frequent requests we received was for a dilution protocol to measure insulin level in horses suspected to be greater than 250 µU/mL," said Ian Harmon, Senior Director, R&D. Ian continues, "In response, rather than validating an external dilution protocol that would involve additional steps for the veterinarian and staff, our engineers designed a way to have the TRUFORMA device automatically dilute the sample for them and run the test with no additional time or steps. The user simply selects the 'Auto Dilute' option from the test menu screen, and the TRUFORMA device takes it from there. The uniqueness of our single-use test cartridges allows us this flexibility of design and is something that no other platform can do." By having the TRUFORMA device perform the dilution automatically on the existing test cartridge, consistency from test-to-test is assured and the staff is freed from having to perform a tedious additional task. The Zomedica R&D team was also able to increase the already industry-leading dynamic range of the standard (or default, undiluted) in-clinic insulin test by 60%! The chart below illustrates the new dynamic ranges for both the default and auto dilute protocols, making the TRUFORMA insulin test for equine plasma the most dynamic test of its kind in the world. T.J. Barclay, DVM, Senior Professional Services Veterinarian for Zomedica, commented, "In recent years, insulin dysregulation in horses and ponies has been increasingly recognized as the most significant risk factor for developing laminitis. In the more severe cases, insulin levels may be above a test's upper limit of detection, rendering us unable to determine by serial monitoring if our treatment is effective. In those cases, quantifying extremely high insulin levels has required sending samples to a reference lab where they can perform sample dilutions. Having a device that gives us results in minutes at the point of care that has a both a high dynamic range by default and a process that dilutes the sample on demand covers all patient types we may encounter, helping us make quicker decisions during the treatment and monitoring process." With the increased dynamic range and new automatic dilution function, along with the consistency, accuracy, and convenience of the original assay, Zomedica has set a new standard for point of care equine insulin testing. The TRUFORMA Insulin assay for equine plasma with automatic sample dilution may be ordered now from Zomedica. For more information, visit About Zomedica Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians with innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW® digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. Zomedica grew revenue 8% in 2024 to $27 million and maintains a strong balance sheet with approximately $65 million in liquidity as of March 31, 2025. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as we work to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices. For more information visit Follow Zomedica Email Alerts: LinkedIn: Facebook: X (formerly Twitter): Instagram: Cautionary Note Regarding Forward-Looking Statements Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information. Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements and our ability to realize upon our business plans and cost control efforts. Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, including international efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to realize the anticipated growth opportunities from our acquisitions; uncertainty as to our ability to supply products in response to customer demand; supply chain risks associated with tariff changes;; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products and purchase of consumables following adoption of our capital equipment; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at Readers are cautioned that this list of risk factors should not be construed as exhaustive. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information. Investor Relations Contact: Zomedica Investor Relationsinvestors@ SOURCE: Zomedica Corp. View the original press release on ACCESS Newswire
Associated Press
21-05-2025
- Business
- Associated Press
Zomedica Launches Enhanced Equine Insulin Assay for the TRUFORMA(R) Diagnostic Platform Featuring an Extended Range and Automatic Sample Dilution
The TRUFORMA Platform now has the widest dynamic range (without manual dilution) available either at the Point of Care or from a Reference Lab ANN ARBOR, MI / ACCESS Newswire / May 21, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ('Zomedica' or the 'Company'), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced an update to one of their fastest growing assays, insulin for equine plasma. This update increases the test's already industry-leading point of care dynamic range and adds a new function, automatic sample dilution, that allows a veterinarian to measure insulin at the highest levels with no additional steps or increase in time-to-result on the TRUFORMA In-Clinic Biosensor Testing Platform. 'When we introduced our equine insulin assay in October of 2024, one of the most frequent requests we received was for a dilution protocol to measure insulin level in horses suspected to be greater than 250 µU/mL,' said Ian Harmon, Senior Director, R&D. Ian continues, 'In response, rather than validating an external dilution protocol that would involve additional steps for the veterinarian and staff, our engineers designed a way to have the TRUFORMA device automatically dilute the sample for them and run the test with no additional time or steps. The user simply selects the 'Auto Dilute' option from the test menu screen, and the TRUFORMA device takes it from there. The uniqueness of our single-use test cartridges allows us this flexibility of design and is something that no other platform can do.' By having the TRUFORMA device perform the dilution automatically on the existing test cartridge, consistency from test-to-test is assured and the staff is freed from having to perform a tedious additional task. The Zomedica R&D team was also able to increase the already industry-leading dynamic range of the standard (or default, undiluted) in-clinic insulin test by 60%! The chart below illustrates the new dynamic ranges for both the default and auto dilute protocols, making the TRUFORMA insulin test for equine plasma the most dynamic test of its kind in the world. T.J. Barclay, DVM, Senior Professional Services Veterinarian for Zomedica, commented, 'In recent years, insulin dysregulation in horses and ponies has been increasingly recognized as the most significant risk factor for developing laminitis. In the more severe cases, insulin levels may be above a test's upper limit of detection, rendering us unable to determine by serial monitoring if our treatment is effective. In those cases, quantifying extremely high insulin levels has required sending samples to a reference lab where they can perform sample dilutions. Having a device that gives us results in minutes at the point of care that has a both a high dynamic range by default and a process that dilutes the sample on demand covers all patient types we may encounter, helping us make quicker decisions during the treatment and monitoring process.' With the increased dynamic range and new automatic dilution function, along with the consistency, accuracy, and convenience of the original assay, Zomedica has set a new standard for point of care equine insulin testing. The TRUFORMA Insulin assay for equine plasma with automatic sample dilution may be ordered now from Zomedica. For more information, visit About Zomedica Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians with innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW® digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. Zomedica grew revenue 8% in 2024 to $27 million and maintains a strong balance sheet with approximately $65 million in liquidity as of March 31, 2025. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as we work to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices. For more information visit Follow Zomedica Cautionary Note Regarding Forward-Looking Statements Except for statements of historical fact, this news release contains certain 'forward-looking information' or 'forward-looking statements' (collectively, 'forward-looking information') within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as 'plan', 'expect', 'project', 'intend', 'believe', 'anticipate', 'estimate' and other similar words, or statements that certain events or conditions 'may' or 'will' occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information. Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements and our ability to realize upon our business plans and cost control efforts. Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, including international efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to realize the anticipated growth opportunities from our acquisitions; uncertainty as to our ability to supply products in response to customer demand; supply chain risks associated with tariff changes;; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products and purchase of consumables following adoption of our capital equipment; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at Readers are cautioned that this list of risk factors should not be construed as exhaustive. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information. Investor Relations Contact: Zomedica Investor Relations [email protected] 1-734-369-2555 SOURCE: Zomedica Corp. press release
Yahoo
19-05-2025
- Business
- Yahoo
Zomedica Unveils Exclusive Fourth Friday at Four Webinar Series to Explore Cutting-Edge Veterinary Innovations
Engaging Sessions to Highlight Game-Changing Technologies, Expert Insights, and Growth Opportunities in Animal Health Featuring Zomedica Products ANN ARBOR, MI / ACCESS Newswire / May 19, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced the launch of a new monthly webinar series designed to highlight its innovative product portfolio, introduce key personnel, showcase manufacturing capabilities, and educate investors and strategic partners on the company's long-term growth strategy. This exclusive webinar series scheduled for the fourth Friday of every month beginning May 23rd, offers a front-row seat to Zomedica's game-changing technologies and strategic vision, providing veterinarians, investors, and industry leaders with an unparalleled opportunity to stay ahead of the curve in animal healthcare. Attendees will gain first-hand insights into cutting-edge advancements that are shaping the future of veterinary medicine while discovering how Zomedica is driving innovation, expanding its market presence, and delivering solutions that improve patient outcomes. Each engaging session will dive deep into Zomedica's groundbreaking technologies, including the: PulseVet® Shock Wave system - A revolutionary, non-invasive therapy accelerating healing in musculoskeletal conditions, setting new standards in veterinary therapeutics. Assisi Loop® and Calmer Canine products - Advanced tPEMF™ (Targeted Pulsed Electromagnetic Field) therapy devices that provide drug-free, highly effective pain and inflammation management, as well as the Calmer Canine therapy for behavioral separation anxiety. TRUFORMA® Diagnostic Platform - A next-generation in-clinic system offering unique, precise, rapid diagnostic testing to support complex veterinary cases with unparalleled accuracy at the point of care. TRUVIEW® Digital Cytology System: Best-in-class imaging and the only fully automated slide prep solution-ensuring consistent quality, telepathology-backed confidence, and a streamlined workflow for faster, more accurate diagnoses in veterinary medicine. VETGuardian® No-Touch Monitoring System - A state-of-the-art, contact-free monitoring solution ensuring continuous remote tracking of vital signs for enhanced patient care. VETIGEL® - An innovative, plant-based hemostatic gel designed for rapid and effective bleeding control, revolutionizing wound management in veterinary medicine. "Zomedica's monthly webinar series isn't just about showcasing our products-it's about building a community of forward-thinking professionals and investors dedicated to advancing animal healthcare," said Larry Heaton, CEO of Zomedica. "Through these interactive sessions, we are offering an exclusive look at our industry-leading technologies, expert-driven discussions, and our commitment to driving growth and innovation in veterinary medicine." Designed to be interactive and insightful, each webinar will feature product demonstrations, in-depth discussions with industry experts, and Q&A opportunities with Zomedica's leadership team. Investors and strategic partners will gain a deeper understanding of the company's expanding market influence, robust R&D pipeline, and vision for sustainable revenue growth and shareholder value. Webinar Registration & Details Don't miss this opportunity to connect with industry experts, discover groundbreaking technologies, and explore new possibilities in veterinary healthcare. The series is open to veterinary professionals, industry partners, investors, and all who are interested in improving the lives of our family pets. To secure your spot in the upcoming sessions, click on the link below or visit About Zomedica Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW® digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. Zomedica grew revenue 8% in 2024 to $27 million and maintains a strong balance sheet with approximately $65 million in liquidity as of March 31, 2025. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as we work to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices. For more information visit Follow Zomedica Email Alerts: LinkedIn: Facebook: X (formerly Twitter): Instagram: Cautionary Note Regarding Forward-Looking Statements Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information. Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements and our ability to realize upon our business plans and cost control efforts. Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, including international efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to realize the anticipated growth opportunities from our acquisitions; uncertainty as to our ability to supply products in response to customer demand; supply chain risks associated with tariff changes;; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products and purchase of consumables following adoption of our capital equipment; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at Readers are cautioned that this list of risk factors should not be construed as exhaustive. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information. Investor Relations Contact: Zomedica Investor Relationsinvestors@ SOURCE: Zomedica Corp. View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19-05-2025
- Business
- Yahoo
Zomedica Unveils Exclusive Fourth Friday at Four Webinar Series to Explore Cutting-Edge Veterinary Innovations
Engaging Sessions to Highlight Game-Changing Technologies, Expert Insights, and Growth Opportunities in Animal Health Featuring Zomedica Products ANN ARBOR, MI / ACCESS Newswire / May 19, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced the launch of a new monthly webinar series designed to highlight its innovative product portfolio, introduce key personnel, showcase manufacturing capabilities, and educate investors and strategic partners on the company's long-term growth strategy. This exclusive webinar series scheduled for the fourth Friday of every month beginning May 23rd, offers a front-row seat to Zomedica's game-changing technologies and strategic vision, providing veterinarians, investors, and industry leaders with an unparalleled opportunity to stay ahead of the curve in animal healthcare. Attendees will gain first-hand insights into cutting-edge advancements that are shaping the future of veterinary medicine while discovering how Zomedica is driving innovation, expanding its market presence, and delivering solutions that improve patient outcomes. Each engaging session will dive deep into Zomedica's groundbreaking technologies, including the: PulseVet® Shock Wave system - A revolutionary, non-invasive therapy accelerating healing in musculoskeletal conditions, setting new standards in veterinary therapeutics. Assisi Loop® and Calmer Canine products - Advanced tPEMF™ (Targeted Pulsed Electromagnetic Field) therapy devices that provide drug-free, highly effective pain and inflammation management, as well as the Calmer Canine therapy for behavioral separation anxiety. TRUFORMA® Diagnostic Platform - A next-generation in-clinic system offering unique, precise, rapid diagnostic testing to support complex veterinary cases with unparalleled accuracy at the point of care. TRUVIEW® Digital Cytology System: Best-in-class imaging and the only fully automated slide prep solution-ensuring consistent quality, telepathology-backed confidence, and a streamlined workflow for faster, more accurate diagnoses in veterinary medicine. VETGuardian® No-Touch Monitoring System - A state-of-the-art, contact-free monitoring solution ensuring continuous remote tracking of vital signs for enhanced patient care. VETIGEL® - An innovative, plant-based hemostatic gel designed for rapid and effective bleeding control, revolutionizing wound management in veterinary medicine. "Zomedica's monthly webinar series isn't just about showcasing our products-it's about building a community of forward-thinking professionals and investors dedicated to advancing animal healthcare," said Larry Heaton, CEO of Zomedica. "Through these interactive sessions, we are offering an exclusive look at our industry-leading technologies, expert-driven discussions, and our commitment to driving growth and innovation in veterinary medicine." Designed to be interactive and insightful, each webinar will feature product demonstrations, in-depth discussions with industry experts, and Q&A opportunities with Zomedica's leadership team. Investors and strategic partners will gain a deeper understanding of the company's expanding market influence, robust R&D pipeline, and vision for sustainable revenue growth and shareholder value. Webinar Registration & Details Don't miss this opportunity to connect with industry experts, discover groundbreaking technologies, and explore new possibilities in veterinary healthcare. The series is open to veterinary professionals, industry partners, investors, and all who are interested in improving the lives of our family pets. To secure your spot in the upcoming sessions, click on the link below or visit About Zomedica Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW® digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. Zomedica grew revenue 8% in 2024 to $27 million and maintains a strong balance sheet with approximately $65 million in liquidity as of March 31, 2025. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as we work to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices. For more information visit Follow Zomedica Email Alerts: LinkedIn: Facebook: X (formerly Twitter): Instagram: Cautionary Note Regarding Forward-Looking Statements Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information. Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements and our ability to realize upon our business plans and cost control efforts. Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, including international efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to realize the anticipated growth opportunities from our acquisitions; uncertainty as to our ability to supply products in response to customer demand; supply chain risks associated with tariff changes;; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products and purchase of consumables following adoption of our capital equipment; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at Readers are cautioned that this list of risk factors should not be construed as exhaustive. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information. Investor Relations Contact: Zomedica Investor Relationsinvestors@ SOURCE: Zomedica Corp. View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-05-2025
- Business
- Yahoo
Zomedica Corp (ZOMDF) Q1 2025 Earnings Call Highlights: Record Revenue Amid Strategic Challenges
Release Date: May 15, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Zomedica Corp (ZOMDF) achieved its 17th consecutive quarter of year-over-year record revenue, with Q1 2025 revenue reaching $6.5 million, a 4% increase from the previous year. The company saw a 32% year-over-year growth in international revenue, driven by expansion into key international markets. Zomedica Corp (ZOMDF) launched five new assays in 2024, contributing to a 41% year-over-year growth in the TrueForma platform during Q1 2025. The company has made strategic investments in infrastructure, such as expanding manufacturing and distribution facilities, which are expected to improve efficiency and reduce costs. Zomedica Corp (ZOMDF) reduced its cash operating expenses by $1.2 million year-over-year and $1 million sequentially, demonstrating a focus on cost management. The company reported a net loss of $63.8 million for Q1 2025, primarily due to a $55.8 million non-cash impairment expense. Diagnostic segment revenues decreased by 25%, with challenges in the Vet Guardian product line impacting overall performance. Sales and marketing expenses increased by 22% compared to the prior quarter, raising concerns about high marketing costs relative to industry averages. Zomedica Corp (ZOMDF) faces challenges in gaining institutional coverage and investment banking relations due to its stock price being below $1 and trading on the OTC market. The company has no immediate plans for a reverse stock split or stock buyback, which may affect investor sentiment regarding stock price appreciation. Warning! GuruFocus has detected 1 Warning Sign with ZOMDF. Q: Why have management options not been repriced or new options issued instead of salary? A: Larry Heaton, CEO: It would not be appropriate to change the strike price of options as shareholders cannot change the price they paid for shares. We periodically issue option grants to employees, which is standard practice, and employees look forward to building value in the company. Q: Why are marketing costs much higher than industry averages? A: Larry Heaton, CEO: Our marketing costs are high as a percentage of revenue because we are essentially a startup with innovative products. We are investing in marketing to introduce new products to the market, which is typical for startups. Q: Are you looking to expand into retail vet stores? A: Larry Heaton, CEO: We currently sell one product line available for retail purchase online through channels like Chewy and PetSmart. We decided not to heavily invest in the retail market due to high advertising costs and are focusing on selling to vets and online channels. Q: Is there a strategy for getting institutional coverage and investment banking relations? A: Larry Heaton, CEO: Institutional analysts will not cover a stock below $1 or on the OTC. We receive frequent calls from investment bankers, but our shareholders are not in favor of a reverse split, which is often suggested. Q: Are you using or planning on using AI to expand the number and rate of discovery of new assays for Truforma? A: Larry Heaton, CEO: We have a good cadence of assays under consideration, but costs limit us to about four assays this year. We will discuss the potential use of AI in this area in our upcoming 4th Friday at 4 session. Q: How profitable has the new Vetagel product been, and are there other consumable product lines you can add? A: Larry Heaton, CEO: Vetagel has a favorable margin, though not as high as products we manufacture ourselves. We focus on adding consumable product lines that leverage our existing client base without significant upfront costs. Q: Why focus heavily on equine when it's only 5% the size of the domestic animal market? A: Larry Heaton, CEO: Equine represents about 14% of clinics, and we have high penetration with PulseVet. Our products are custom-designed for equine, and we have a strong relationship with this market. Q: What is the status of TrueView, and how is it monetized? A: Larry Heaton, CEO: We are near completion of the AI component and plan a full launch soon. TrueView is monetized via a subscription model with additional charges for AI reports and pathologist reviews. Q: Do you plan on hiring a new CFO to replace Scott? A: Larry Heaton, CEO: Mike Zzelke is doing a good job as interim CFO. While we may eventually fill the position, it is not a priority now, and it represents cost savings. Q: Are there any plans to increase the stock share price? A: Mike Zzelke, VP of Finance: We are focused on delivering growth and profitability to drive stock price appreciation. We continue to evaluate options for listing on a major exchange, but operational improvements are our primary focus. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
